How tumor-associated macrophages produce lactate and influence cancer growth
Lactate production by tumor associated macrophages promotes tumorigenesis
['FUNDING_R01'] · UNIVERSITY OF CHICAGO · NIH-11030791
This study is looking at how certain immune cells called tumor-associated macrophages help cancer grow by producing a substance called lactate, and it aims to find new ways to improve cancer treatments by changing how these cells behave.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CHICAGO (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-11030791 on ClinicalTrials.gov |
What this research studies
This research investigates the role of tumor-associated macrophages (TAMs) in cancer progression, focusing on how they produce lactate and adopt a phenotype that supports tumor growth. By examining the environmental conditions that lead to the M2-like polarization of these immune cells, the study aims to uncover the molecular mechanisms involved. The researchers will utilize both human samples and experimental animal models to explore how lactate production affects macrophage behavior and cancer therapy outcomes. The ultimate goal is to identify potential therapeutic targets that could enhance anti-cancer treatments by manipulating TAMs.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with various types of cancer who may benefit from therapies targeting tumor-associated macrophages.
Not a fit: Patients with non-cancerous conditions or those whose tumors do not involve significant macrophage activity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively target tumor-associated macrophages, improving cancer treatment outcomes.
How similar studies have performed: Previous studies have shown promising results in targeting tumor-associated macrophages for cancer therapy, indicating that this approach has potential for success.
Where this research is happening
CHICAGO, UNITED STATES
- UNIVERSITY OF CHICAGO — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BECKER, LEV — UNIVERSITY OF CHICAGO
- Study coordinator: BECKER, LEV
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer, anti-cancer therapeutic, anti-cancer therapy